India · Delayed Price · Currency is INR Syngene International Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw 3% revenue growth, with Q4 rebounding 13% sequentially despite Librela headwinds. FY 2027 is expected to be flat as Librela impact fades, with margins guided in the mid-20s and growth anticipated from FY 2028 as new capabilities and contracts mature.
-
Q3 revenue declined 3% year-on-year due to a single large molecule product impact, while underlying business showed steady growth. Full-year revenue is now expected to decline 3%-5%, with the product headwind persisting into FY 2027. Research services and CDMO segments continue to expand capabilities and utilization.
-
Q2 FY26 revenue grew 2% YoY to INR 911 crore, with research services outpacing CDMO, but EBITDA and PAT declined due to inventory correction and higher costs. Strategic investments in clinical trials, ADCs, and peptides position the company for future growth, with full-year guidance maintained.
-
Q1 FY26 delivered 11% revenue growth and 21% EBITDA growth, led by research services and operational milestones. Full-year guidance is maintained, with inventory adjustments in biologics expected to impact growth in coming quarters.
Fiscal Year 2025
-
India's clinical research market is rapidly expanding, driven by patient diversity, regulatory improvements, and cost advantages. Syngene has scaled its clinical research capabilities, offering integrated, end-to-end services and leveraging advanced technologies, with strong profitability and no major capacity constraints. A recent global trial win highlights its growing presence.
-
Q4 and FY 2025 saw resilient revenue growth, margin stability, and strategic U.S. biologics facility acquisition. FY 2026 guidance points to early-teens underlying growth, with reported growth tempered by inventory normalization and margin moderation due to new facility ramp-up.
-
Q3 saw an 11% year-over-year revenue increase and a 23% rise in operating EBITDA, with margins improving to 30.1%. Growth was driven by Discovery Services and biologics, while full-year guidance was revised to single-digit revenue growth and flat EBITDA.
-
Q2 FY2025 saw flat YoY performance but 13% sequential revenue growth, with strong client interest in discovery and biologics services. Margin recovery and growth are expected in H2, with full-year revenue likely at the lower end of guidance.
-
Revenue and profit declined year-over-year in Q1 FY25, but leading indicators and client activity point to improved momentum in H2. Full-year guidance is unchanged, with EBITDA margin expected in the high 20s and PAT growth in single digits.